Stereotactic Body Radiotherapy for Liver Tumors

Completed · Not applicable

Conditions studied: Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma

In brief

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Key facts

Study ID

NCT01347333

Run by

Mercy Research

People needed

23

Starts

2008-09-01

Expected to finish

2016-09-01

Last updated by the study team

2020-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient age >= 18 years
• Zubrod performance status of 0-3
• Oligometastases (1-3) with aggregate tumor diameter < 6 cm
• Metastases from neuroendocrine tumors with functional endocrine syndromes for symptom palliation
• Unresectable hepatocellular carcinoma (HCC)
• Unresectable intrahepatic cholangiocarcinoma (IHCC)
• Maximum tumor diameter < 6 cm
• Adequate liver function:
• Total bilirubin < 3 mg/dL Serum albumin > 2.5 g/dL Serum levels of liver enzymes < 3 times the upper limit of normal Normal PT and PTT unless patient is receiving anticoagulant medication
• Signed study-specific consent form

You may not qualify if…

• Maximum tumor diameter > 6 cm
• Prior radiotherapy to the liver
• Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females
• Patients with psychiatric or addictive disorder that would preclude obtaining informed consent

Where it is running

• St. John's Mercy Medical Center — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.